Ocular Therapeutix (OCUL) Capital Expenditures (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Capital Expenditures of $3.4 million for Q2 2026, up 170.44% year-over-year from $1.2 million in Q2 2025, and down 27.78% on a QoQ basis from $4.7 million in Q1 2026.
Ocular Therapeutix (OCUL) Capital Expenditures (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Capital Expenditures for 14 years, with the latest figure at $3.4 million in Q2 2026.
- Capital Expenditures for Q2 2026 came in at $3.4 million, up 170.44% year-over-year; the trailing twelve-month figure through Jun 2026 was $16.9 million (up 386.05% YoY), and the FY2025 annual result was $12.0 million, up 832.45% from the prior year.
- Capital Expenditures fell to $3.4 million in Q2 2026, from $4.7 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $6.0 million in Q3 2025 and troughed at $89000.0 in Q3 2024.
- A 5-year average of $1.7 million and a median of $1.0 million in 2022 frame the typical range for Capital Expenditures.
- The widest annual swing landed in 2024, when Capital Expenditures plunged 88.4%; it then soared 6633.71% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $2.2 million in 2022, then sank by 78.65% to $459000.0 in 2023, then tumbled by 55.99% to $202000.0 in 2024, then surged by 1305.45% to $2.8 million in 2025, then grew by 18.6% to $3.4 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $3.4 million in Q2 2026, $4.7 million in Q1 2026, and $2.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.37 Mn |
| Jun 30, 2026 | 3.37 Mn |
| Mar 31, 2026 | 1.33 Mn |
| Mar 31, 2026 | 1.33 Mn |
| Dec 31, 2025 | 2.84 Mn |
| Dec 31, 2025 | 2.84 Mn |
| Sep 30, 2025 | 5.99 Mn |
| Sep 30, 2025 | 5.99 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 45,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -212,000.00 |
| Jun 30, 2024 | -212,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Mar 31, 2024 | 255,000.00 |